250+ investors that invest in your industry and stage
Any industry
Energy
Proptech
Community
Health Care
Gaming
Artificial Intelligence
Climate
Biotech
Impact
Google
EdTech
Sustainability
Venture Capital
Clean Energy
Finance
Retail
Infrastructure
Digital Media
Local
Enterprise Software
Email
Travel
Recruiting
Platforms
Fitness
Wine and Spirits
Crowdfunding
Social
CleanTech
Mobile Apps
InsurTech
LGBT
Oil and Gas
Fashion
Theatre
Non Profit
SaaS
Renewable Energy
Sporting Goods
Social Impact
Celebrity
Cryptocurrency
Restaurants
Machine Learning
Blockchain
Agriculture (AgTech)
Media (Entertainment)
Facebook
Publishing
Beauty
Real Estate
Life Science
B2B
Film
Web3
Big Data
Organic Food
Video Games
Medical Device
Medical
Wellness
Education
Payments
Art
Social Media
Photography
Music
Franchise
Android
Mobile
Internet
Legal
Construction
eSports
Manufacturing
Sports
Automotive
Hospitality
Financial Services
Mobile Advertising
Cannabis
Biotechnology
FinTech
Consumer
Marketplace
Hardware
Transportation
Food and Beverage
Social Network
Enterprise
Software
Any country
Australia
South Korea
Europe
Brazil
Indonesia
Singapore
Saudi Arabia
Africa
Oceania
LATAM
Asia
Middle East
Costa Rica
Gibraltar
Bahrain
Liberia
Mexico
Lebanon
Norway
Mauritius
Italy
Israel
Taiwan
Tunisia
Zambia
Russian Federation
Tajikistan
Sweden
Zimbabwe
Togo
Puerto Rico
San Marino
Nigeria
Jamaica
Honduras
Isle of Man
Mozambique
Luxembourg
Albania
Pakistan
Romania
Bangladesh
Greece
Finland
Kazakhstan
Kenya
Cayman Islands
Cambodia
Algeria
Cameroon
Oman
Guatemala
Colombia
China
Seychelles
Ireland
New Zealand
Cyprus
India
Germany
Canada
United Kingdom
Qatar
South Africa
Spain
Sri Lanka
Armenia
Azerbaijan
Austria
Barbados
Argentina
Vietnam
United Arab Emirates
Bulgaria
Belarus
Estonia
Belgium
Bermuda
Bolivia
Egypt
France
Bahamas
Czech Republic
Chile
Denmark
Faroe Islands
Georgia
Ecuador
Belize
Croatia
Dominican Republic
Hong Kong
Switzerland
Ethiopia
Grenada
Ghana
Iraq
Hungary
Iceland
Jersey
Jordan
Kuwait
Liechtenstein
Lithuania
Morocco
Latvia
Mali
Marshall Islands
Myanmar
Malta
Malaysia
Nicaragua
Namibia
Peru
Philippines
Poland
Panama
Portugal
Rwanda
Sierra Leone
Serbia
Slovenia
Senegal
El Salvador
Thailand
Tanzania
Uruguay
Turkey
Ukraine
Uganda
Uzbekistan
Venezuela
United States
Japan
Angel Investors
VC Funds
All Investors
Download Find emails Save list

Top 50 Biotechnology Startup Investors in Germany (June 2026)

The most active venture capital funds and angel investors investing in Germany Biotechnology startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Germany Biotechnology startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
HTGF (High-Tech Gruenderfonds)
VC Fund
47 Germany, Switzerland, United States Seed, Series A Software, Biotechnology, Information Technology $909k–$33M
Boehringer Ingelheim Venture Fund
VC Fund
18 United States, Germany, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $1.3M–$50M
MIG Capital
VC Fund
16 Germany, France, Austria Series A, Series B Biotechnology, Health Care, Therapeutics $1.6M–$54M
KfW
VC Fund
16 Germany, India, Kenya Series A, Series B Biotechnology, Software, Health Care $2.2M–$17M
Bayern Kapital
VC Fund
15 Germany, United States, Finland Seed, Series A Software, Health Care, Information Technology $1.1M–$31M
NRW.BANK
VC Fund
15 Germany, United States, France Seed, Series A, Series B Information Technology, Software, Biotechnology $110k–$71M
Wellington Partners
VC Fund
9 Germany, United States, United Kingdom Series A, Series B Health Care, Biotechnology, Medical $3.1M–$55M
b.value AG
VC Fund
9 Germany, Poland Seed, Series A Biotechnology, Manufacturing, Chemical $478k–$40M
IFB Innovationsstarter
VC Fund
8 Germany, United States Seed, Grant Software, SaaS, Artificial Intelligence $80k–$3M
TGFS - Technologiegründerfonds Sachsen
VC Fund
8 Germany, United States Seed, Series A Software, Information Technology, Manufacturing $932k–$15M
BioMedPartners
VC Fund
8 Switzerland, Germany, France Series A, Series B, Series C Biotechnology, Health Care, Medical $4.9M–$83M
Techno Venture Management
VC Fund
7 United States, Germany, United Kingdom Series B, Series A Biotechnology, Health Care, Pharmaceutical $4.7M–$44M
eCAPITAL ENTREPRENEURIAL PARTNERS
VC Fund
6 Germany, United States, Italy Series A, Series B Information Technology, Software, Manufacturing $2.7M–$35M
coparion
VC Fund
6 Germany, Switzerland, United States Series A, Seed, Series B Software, SaaS, FinTech
Forbion Capital Partners
VC Fund
6 United States, United Kingdom, The Netherlands Series B, Series A, Series C Biotechnology, Health Care, Medical $12M–$176M
bm-t beteiligungsmanagement thuringen
VC Fund
6 Germany, United States Seed, Series A Software, Information Technology, Health Care $461k–$18M
bmp Ventures
VC Fund
6 Germany, United States, Austria Seed, Series A Software, Information Technology, Manufacturing $30k–$5.9M
Brandenburg Kapital
VC Fund
5 Germany, United Kingdom Seed, Series A Software, Information Technology, Health Care $823k–$14M
Creathor Ventures
VC Fund
5 Germany, Switzerland, United States Series A, Series B Software, Health Care, Biotechnology $2M–$20M
BayBG Venture Capital
VC Fund
5 Germany, Italy, United States Series A, Series B Software, Information Technology, Health Care $428k–$23M
IBB Ventures
VC Fund
5 Germany, United States, United Kingdom Seed, Series A Software, Health Care, SaaS $1M–$15M
EMBL Ventures
VC Fund
5 Germany, Austria, Ireland Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $3.9M–$70M
German Federal Ministry of Research, Technology and Space
VC Fund
4 Germany, United States, Denmark Grant, Seed, Series B Biotechnology, Medical, Health Care $300k–$25M
BlueYard Capital
VC Fund
4 United States, Germany, United Kingdom Seed, Series A Software, Biotechnology, Internet $1.2M–$47M
S-Venture Capital Dortmund
VC Fund
4 Germany Series B, Series A Biotechnology, Guides, Genetics $3.6M–$9M
Seed Fonds Aachen
VC Fund
4 Germany Seed, Series A Biotechnology, Medical, Health Care $2.2M–$6M
CPT Capital
VC Fund
4 United States, Israel, United Kingdom Series A, Seed, Series B Food and Beverage, Biotechnology, Food Processing $1.3M–$226M
Grazia Equity
VC Fund
4 Germany, United States, Switzerland Series A, Series B, Seed Internet, E-Commerce, Biotechnology $1.1M–$59M
better ventures
VC Fund
4 Germany, Switzerland Pre-Seed, Seed, Series A Software, Food and Beverage, E-Commerce $114k–$5.8M
Andera Partners
VC Fund
4 France, United States, Germany Series B, Private Equity Biotechnology, Health Care, Medical $14M–$247M
Amino Collective
VC Fund
4 United States, United Kingdom, Germany Seed, Series A, Pre-Seed Health Care, Biotechnology, Medical $125k–$26M
EIC Fund
VC Fund
4 Germany, The Netherlands, Austria Pre-Seed, Seed Biotechnology, Health Care, Information Technology
LSP BioVentures
VC Fund
4 United States, Germany, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $5.3M–$176M
EQT Ventures
VC Fund
4 Sweden, Germany, United States Series A, Seed, Series B Software, Artificial Intelligence, Information Technology $3.3M–$100M
Counteract
VC Fund
3 United Kingdom, United States, Germany Seed, Series A, Pre-Seed Environmental Engineering, CleanTech, AgTech
Ananda Impact Ventures
VC Fund
3 Germany, United Kingdom, Finland Seed, Series A Health Care, Software, Information Technology
EQT Life Sciences
VC Fund
3 United States, The Netherlands, Switzerland Series A, Series B, Series C Biotechnology, Health Care, Therapeutics
TechVision Fund
VC Fund
3 Germany, Spain Seed, Series A, Pre-Seed Software, Health Care, Manufacturing
DvH Ventures
VC Fund
3 Germany, Austria, United Kingdom Seed, Series A Health Care, Financial Services, FinTech
Gruenderfonds Ruhr
VC Fund
3 Germany Series A, Series B, Seed Health Care, Biotechnology, Information Technology $4.9M–$95M
Kurma Partners
VC Fund
3 France, Switzerland, Spain Series A, Seed, Series B Health Care, Biotechnology, Medical $2.3M–$80M
Agronomics
VC Fund
3 United States, Finland, Germany Series A, Seed, Series B Biotechnology, Food and Beverage, Food Processing $894k–$55M
Elevat3 Capital
VC Fund
3 Germany, United Kingdom Series A, Series B, Post-IPO Equity FinTech, Apps, Social $45M–$157M
Taavet Hinrikus
Angel
3 United Kingdom, United States, Estonia Seed, Series A, Series B FinTech, Software, Financial Services $1M–$52M
TVM Capital
VC Fund
3 United States, Germany, United Kingdom Series B, Series C Biotechnology, Health Care, Pharmaceutical $7.5M–$55M
Think.Health
VC Fund
3 Germany, United States, France Seed, Series A, Series B Health Care, Biotechnology, Medical Device $1.1M–$28M
Andrew Keys
Angel
3 United States, India, Norway Seed, Pre-Seed, Series A Software, Finance, Blockchain $1M–$34M
OCCIDENT
VC Fund
3 Germany, Switzerland, Slovenia Series A, Series B, Series C Health Care, Biotechnology, Medical Device $2.1M–$140M
Good Seed Ventures
VC Fund
3 Germany, Israel, United States Seed, Series A, Pre-Seed Food and Beverage, Food Processing, Biotechnology $25k–$21M
M Ventures
VC Fund
3 United States, United Kingdom, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2.4M–$100M
Access all 701 investors in Germany Biotechnology startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

HTGF (High-Tech Gruenderfonds)
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 47 investments in Germany Biotechnology startups

High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Information Technology
  • Stage:Seed, Series A
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 542
  • Round size: Seed $909k–$6.5M; Series A $3M–$33M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: Likely still investing — raised $522M in 2022

Portfolio highlights

  • Sdui — Sdui is the solution for mobile communication in schools. With amazingly easy features for messaging, timetables and a wide range of third party integrations, the app digitizes processes and reduces administrative effort. Within two years, Sdui has reached hundreds of institutions and grown a serious reputation in the educational market.
  • envelio — We are driving forward the energy transition with our smart grid solutions for grid operators. Get information now and plan smart!
  • Atriva Therapeutics — Therapies against viral infections. First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.
Show all investments...

Boehringer Ingelheim Venture Fund
VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 18 investments in Germany Biotechnology startups

Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Germany, Switzerland

Investor stats

  • Total investments: 94
  • Round size: Seed $1.3M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: May invest from a new fund soon — raised $250M in 2018

Portfolio highlights

  • Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
  • Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
  • Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
Show all investments...

MIG Capital
VC Fund · München, Bayern, Germany · 16 investments in Germany Biotechnology startups

MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B
  • Geography: Germany, France, Austria

Investor stats

  • Total investments: 93
  • Round size: Series A $2.2M–$28M; Series B $1.6M–$54M
  • Lead/follow: 45% lead, 55% follow
  • Last fund: May invest from a new fund soon — raised $70M in 2014

Portfolio highlights

  • AMSilk — AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.
  • Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
  • ASTRA Therapeutics — Astra - Therapeutics
Show all investments...

KfW
VC Fund · Frankfurt, Hessen, Germany · 16 investments in Germany Biotechnology startups

KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the Länder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Series A, Series B
  • Geography: Germany, India, Kenya

Investor stats

  • Total investments: 140
  • Round size: Series A $2.2M–$7.7M; Series B $3.3M–$17M
  • Lead/follow: 12% lead, 88% follow

Portfolio highlights

  • Vectoflow — Vectoflow is an innovative company developing fluid-dynamic metrology devices for fluid flow and dynamics measurement. It offers standardized and customized flow measurement technology that measures the static and total pressure, velocity, and angle of attack of a flow. These products are used in motorsport, aviation, turbine machine development,and research sectors.
  • Electrochaea — Electrochaea is commercializing a disruptive, scalable technology to convert electric power into methane, the principal component of natural gas. Using CO2 as a feedstock gas, power can be efficiently converted to renewable natural gas for power storage, for transportation fuels, or for transmission via a natural gas network. The company licensedtechnology from the University of Chicago and is led by the Nidus Partners, a St. Louis investment group specializing in renewable energy. Mich Hein, a Nidus Managing Partner, serves as CEO.Electrochaea has developed a commercially viable and disruptive solution for utility-scale energy storage, grid balancing, and carbon reuse. Their proprietary process converts low-cost and stranded electricity and carbon dioxide into pipeline-grade renewable gas for direct injection into the existing natural gas grid, a conversion process known as “power-to-gas”.
  • CryoTherapeutics — CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries.
Show all investments...

Bayern Kapital
VC Fund · Landshut, Bayern, Germany · 15 investments in Germany Biotechnology startups

Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.

Show more...

Investment focus

  • Industry: Software, Health Care, Information Technology
  • Stage:Seed, Series A
  • Geography: Germany, United States, Finland

Investor stats

  • Total investments: 227
  • Round size: Seed $1.1M–$5.5M; Series A $3.9M–$31M
  • Lead/follow: 15% lead, 85% follow
  • Last fund: May invest from a new fund soon — raised $26M in 2010

Portfolio highlights

  • EcoG — EcoG connects and enables monetizing charging infrastructure with an API-software platform. EcoG is the first cloud-based platform to enable shared revenue streams and value-added services in fast charging. With EcoG a personalized and customized EV fast charging experience is easy to implement and operate.
  • XO Life — XO Life is to build the largest real-world evidence platform for patient insights for all medications and therapies. Together with one of Europe's leading research institutes for patient-centered research, the PROMIS Institute Germany of the Charité, and various pharmaceutical manufacturers, patient experiences are to be recorded in astandardized and systematic manner across a wide range of diseases. Patients are to be enabled to record their therapy course and outcome independently as well as scientifically validated so that these patient insights from real treatment practice can be used in the life science industry and by medical professions.
  • inContAlert — inContAlert is a deep tech start-up disrupting the field of incontinence. The technology of inContAlert helps people with bladder dysfunction to monitor the filling level of their urinary bladder.inContAlert, therefore, developed an mHealth device, which collects and analyzes data with the help of deep learning algorithms. The information is thendisplayed on an app and sends an alert to incontinence patients when a predefined filling level is reached. inContAlert thereby minimizes the risk of an uncontrolled loss of urine or the harmful distension of the bladder. With the help of inContAlert, incontinence patients can go back to normal and live a carefree life.
Show all investments...

NRW.BANK
VC Fund · Düsseldorf, Nordrhein-Westfalen, Germany · 15 investments in Germany Biotechnology startups

NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.

Show more...

Investment focus

  • Industry: Information Technology, Software, Biotechnology
  • Stage:Seed, Series A, Series B
  • Geography: Germany, United States, France

Investor stats

  • Total investments: 119
  • Round size: Seed $110k–$7.7M; Series A $3.8M–$33M; Series B $3.8M–$71M
  • Lead/follow: 21% lead, 79% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • odacova — Odacova is a SaaS company that provides individualized nutrition for corporate cafeterias and employee eating, utilizing web, Android, and iOS platforms.
  • eleQtron — eleQtron creates and operates quantum computers based on trapped ions, radio frequency control, and Magnetic Gradient Induced Coupling (MAGIC). It also puts forward novel ideas for scalable quantum processors based on RF-controlled trapped ions. eleQtron will run MAGIC quantum computers and provide quantum computing performance on a subscriptionbasis.
  • Cellbox Solutions — Cellbox Solutions is a young technology company that focuses on innovative logistic solutions for the global BioMed industry.
Show all investments...

Wellington Partners
VC Fund · Munich, Bayern, Germany · 9 investments in Germany Biotechnology startups

Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B
  • Geography: Germany, United States, United Kingdom

Investor stats

  • Total investments: 193
  • Round size: Series A $3.1M–$33M; Series B $6.7M–$55M
  • Lead/follow: 30% lead, 70% follow
  • Last fund: May invest from a new fund soon — raised $222M in 2019

Portfolio highlights

  • nyra health — myReha is an artificial intelligence and evidence-based neurological research tablet app that offers a revolutionary form of therapy. myReha was founded in 2020 and was headquartered in Vienna, Austria.
  • UroMems — The device is developing an active implantable medical device based on the cutting edge technologyl in the field of embedded systems and micro-technologies for the development of its products.
  • Heliatek — As the technology leader in organic photovoltaics, Heliatek develops, produces and distributes industrial-grade organic PV solar solutions for virtually any building surface (horizontal, vertical, curved, rigid, and flexible). Heliatek stands for energy solutions designed for various traditional and never been possible before applications based onits unique features – it is ultra-light, flexible and truly green. HeliaSol® is a ready-to-use solution, ideal for retrofitting on existing building structures. HeliaFilm® is tailor-made solar film for companies in the building and construction material industry, to integrate into their façade or roof system products. Heliatek currently employs about 160 people at the Dresden and Ulm locations in Germany.The Free State of Saxony, the Federal Republic of Germany, and the European Union funded research and development, as well as the installation of the production technology.
Show all investments...

b.value AG
VC Fund · Dortmund, Nordrhein-Westfalen, Germany · 9 investments in Germany Biotechnology startups

b.value AG are into Biotechnology investments.

Show more...

Investment focus

  • Industry: Biotechnology, Manufacturing, Chemical
  • Stage:Seed, Series A
  • Geography: Germany, Poland

Investor stats

  • Total investments: 14
  • Round size: Seed $478k–$2.5M; Series A $3M–$40M
  • Lead/follow: 14% lead, 86% follow

Portfolio highlights

  • PL BioScience — STEM CELL EXPANSION IN SAFE AND REPRODUCIBLE CONDITIONS. We deliver advanced 2D and 3D cell culture solutions based on human Platelet Lysate – for basic research, cellular therapeutics and clinical applications. Choose between different safety grades meeting your needs: Research Grade, GMP Grade or GMP-Clinical Grade.
  • Cultimate Foods — At Cultimate, we are transforming the flavor and aroma industry with natural innovative ingredients.
  • traceless materials — traceless materials offer a holistically sustainable alternative to plastics: 100% biobased on plant residues, compostable under natural conditions, and free of toxic chemicals. For a future free of pollution and waste!
Show all investments...

IFB Innovationsstarter
VC Fund · Hamburg, Hamburg, Germany · 8 investments in Germany Biotechnology startups

The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.

Show more...

Investment focus

  • Industry: Software, SaaS, Artificial Intelligence
  • Stage:Seed, Grant
  • Geography: Germany, United States

Investor stats

  • Total investments: 77
  • Round size: Seed $658k–$3M; Grant $80k–$165k
  • Lead/follow: 40% lead, 60% follow

Portfolio highlights

  • mo:re GmbH — We offer standardized tissue cultures and protocols to better predict drug responses and investigate disease models.
  • Flexvelop — Flexvelop combines financial technology with circular economy to add innovative values to the core function of equipment funding.Local vendors and online-shops integrate Flexvelop as a seamless embedded payment option. Business customers are now able to #flex new equipment per click right at the point of sale. Insurance is already covered, andour customers have now the weekly option, to buy- or return their equipment, easily. This enables a new world of worry-free and flexible business growth.We #flex business equipment from €300 up to €20.000 per item; e.g. coffee-machines, laptops, gym- or dental-equipment,... anything you need for your business.NEXT GENERATION PAYMENTS + Technological Innovation: fully automatic embedded payment option + Economical Innovation: optionality (rent/buy/return) + insurance included + Ecological Innovation: sustainability (contributing to a circular economy) = Enabling worry-free flexible business developmentForget renting. Forget leasing. Grow smart - flex it!
  • eleQtron — eleQtron creates and operates quantum computers based on trapped ions, radio frequency control, and Magnetic Gradient Induced Coupling (MAGIC). It also puts forward novel ideas for scalable quantum processors based on RF-controlled trapped ions. eleQtron will run MAGIC quantum computers and provide quantum computing performance on a subscriptionbasis.
Show all investments...

TGFS - Technologiegründerfonds Sachsen
VC Fund · Leipzig, Sachsen, Germany · 8 investments in Germany Biotechnology startups

TGFS - Technologiegruenderfonds Sachsen is an early stage VC fund targeting high tech startups with strong growth potential. The fund invests into ventures located in Saxony/Germany, Europe's leading semiconductor cluster. The team has invested into more than 120 companies so far, including more than 40 investments from the currentfund.

Show more...

Investment focus

  • Industry: Software, Information Technology, Manufacturing
  • Stage:Seed, Series A
  • Geography: Germany, United States

Investor stats

  • Total investments: 137
  • Round size: Seed $932k–$4.8M; Series A $1.9M–$15M
  • Lead/follow: 23% lead, 77% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Peeriot — Peeriot is a B2B software high-tech startup with a breakthrough in IoT. Peeriot offers a low-code software suite that simplifies IoT data sharing by tenfold.
  • Primogene
  • b.sure — b.sure help brands, agencies and event organizers to make their offline events as measurable as their online marketing.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
BioMedPartners
VC Fund · Basel, Basel-Stadt, Switzerland · 8 investments in Germany Biotechnology startups

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: Switzerland, Germany, France

Investor stats

  • Total investments: 86
  • Round size: Series A $5.3M–$26M; Series B $4.9M–$83M; Series C $5.8M–$48M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: May invest from a new fund soon — raised $113M in 2018

Portfolio highlights

  • Vaximm — Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinicaltrials in 2011.
  • iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
  • Affimed — At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim toovercome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Show all investments...

Techno Venture Management
VC Fund · Boston, Massachusetts, United States · 7 investments in Germany Biotechnology startups

Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series B, Series A
  • Geography: United States, Germany, United Kingdom

Investor stats

  • Total investments: 99
  • Round size: Series A $4.7M–$22M; Series B $5.2M–$44M
  • Lead/follow: 20% lead, 80% follow

Portfolio highlights

  • Streaming21 — Streaming21 is a solution provider of seamless on-demand and IP broadcasting service platform for connected digital home.
  • Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
  • Precision Therapeutics — Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.
Show all investments...

eCAPITAL ENTREPRENEURIAL PARTNERS
VC Fund · Münster, Nordrhein-Westfalen, Germany · 6 investments in Germany Biotechnology startups, 6 in the past 12 months

eCAPITAL is a venture capital investor that provides early to growth stage funding to technology and deep tech companies.

Show more...

Investment focus

  • Industry: Information Technology, Software, Manufacturing
  • Stage:Series A, Series B
  • Geography: Germany, United States, Italy

Investor stats

  • Total investments: 117
  • Round size: Series A $2.7M–$14M; Series B $3.1M–$35M
  • Lead/follow: 70% lead, 30% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Cleafy — A new era for online fraud management: Cleafy combines in real-time all the most advanced fraud detection technologies in one fraud management solution.
  • VisioLab — Instantly scan products for self-checkout, using the iPad camera - no barcodes needed. Designed for speed, simplicity and human centricity.
  • QuoIntelligence — Our finished intelligence will significantly reduce your operational risks and allow you to make informed security decisions.
Show all investments...

coparion
VC Fund · Cologne, Nordrhein-Westfalen, Germany · 6 investments in Germany Biotechnology startups, 6 in the past 12 months

Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.

Show more...

Investment focus

  • Industry: Software, SaaS, FinTech
  • Stage:Series A, Seed, Series B
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 97
  • Lead/follow: no public data

Portfolio highlights

  • Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
  • Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
  • Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Show all investments...

Forbion Capital Partners
VC Fund · Naarden, Noord-Holland, The Netherlands · 6 investments in Germany Biotechnology startups

Impacting the future of medicine.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, The Netherlands

Investor stats

  • Total investments: 171
  • Round size: Series A $14M–$176M; Series B $12M–$155M; Series C $12M–$113M
  • Lead/follow: 50% lead, 50% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
  • Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
  • Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
Show all investments...

bm-t beteiligungsmanagement thuringen
VC Fund · Erfurt, Thuringen, Germany · 6 investments in Germany Biotechnology startups

bm|t supports innovative and growth-oriented companies in Thuringia with equity investments and venture capital.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: Germany, United States

Investor stats

  • Total investments: 61
  • Round size: Seed $461k–$7M; Series A $1.1M–$18M
  • Lead/follow: 64% lead, 36% follow

Portfolio highlights

  • Leapter — Leapter is the trust engine for AI agents. Build logic tools for AI Agents and de-risk your AI workflows with visual, executable blueprints for deterministic decisions.
  • Peeriot — Peeriot is a B2B software high-tech startup with a breakthrough in IoT. Peeriot offers a low-code software suite that simplifies IoT data sharing by tenfold.
  • warmwind — warmwind operates as an AI operating system for visual process automation.
Show all investments...

bmp Ventures
VC Fund · Berlin, Berlin, Germany · 6 investments in Germany Biotechnology startups, 7 in the past 12 months

bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.

Show more...

Investment focus

  • Industry: Software, Information Technology, Manufacturing
  • Stage:Seed, Series A
  • Geography: Germany, United States, Austria

Investor stats

  • Total investments: 118
  • Round size: Seed $151k–$3.4M; Series A $30k–$5.9M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • Sedivention — Fight obesity within 20 minutes - fast, effective, long-term. A new weight-loss therapy for the treatment of obesity. Just a view minutes will change your life.
  • Solar Materials — SOLAR MATERIALS developed a recycling technology for solar modules, which recovers all raw materials for a circular solar industry.
  • Litherm Technologies — Litherm Technologies GmbH is a German deep‑tech startup focused on decarbonizing lime and cement production using fully electric kiln technology.
Show all investments...

Brandenburg Kapital
VC Fund · Potsdam, Brandenburg, Germany · 5 investments in Germany Biotechnology startups

With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: Germany, United Kingdom

Investor stats

  • Total investments: 72
  • Round size: Seed $823k–$6.1M; Series A $2.7M–$14M
  • Lead/follow: 43% lead, 57% follow

Portfolio highlights

  • Kupando — Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
  • ThinkSono — ThinkSono Guidance enables any non-ultrasound trained healthcare professional to scan for blood clots (DVT). It reduces waiting times, negative DVT cases and can be used at the point of care.
  • ALVA Energie — Alva delivers turnkey solar systems with integrated energy, heating, and e-mobility for buildings
Show all investments...

Creathor Ventures
VC Fund · Bad Homburg, Hessen, Germany · 5 investments in Germany Biotechnology startups

We have been investing at the frontier of technology and science for over 30 years. We know what it takes to succeed.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Series A, Series B
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 93
  • Round size: Series A $2M–$12M; Series B $5.1M–$20M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: May invest from a new fund soon — raised $94M in 2016

Portfolio highlights

  • SIRION BIOTECH — Viral Vector Technology as key enabler for innovative therapeutics. Viral vectors are a tool commonly used by molecular biologists to deliver genetic material into cells. This technique enables research of gene function and innovative therapeutics designed to correct defective genes and cancer. These technologies also assist in the discovery ofnew drug, food and cosmetic compounds. SIRION is a global leader in viral vector technology for gene modification of mammalian cells. Along with custom services, the company stands ready to outlicense its unique technologies. An initial target currently being pursued by one of SIRION's partners is a gene therapeutic for cervical cancer. The company started business in 2007 and since then has been changing the paradigm of viral vector supplies. Specifically, all commonly applied vector types are now available within a matter of weeks - adenovirus, adeno-associated virus (AAV) and lentivirus - and a full range of virus related services is at your fingertips spanning from particle production to virus driven cell modelling, all at highest titers and in quantities required for preclinical, clinical and animal testing.The company is easily accessible with presence in Munich, Tokyo, New Hampshire and Tel Aviv. Commercial arrangements range from fee-for-service over exclusive rights on single clones all the way to milestone & licensing arrangements. The business model proves successful: an annual 70% growth since 2007 and experienced in more than 500 projects for both the academic and industry sector.The company is privately held and has over the years raised funds from 8 investors both private and government. In order to support further growth and to benefit from technology development in this exciting industry, the company welcomes new investors. Please contact Management for further information about the company and its future plans.
  • CryoTherapeutics — CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries.
  • Chundsell Medicals — Chundsell Medicals AB was founded in 2007 as a spin off from Karolinska Institutet, Solna, in order to commercialize the research results of Chunde Li and his group on prostate cancer genomics. The first product: The Prostatype® Test System can assess prostate cancer aggressiveness in conjunction with currently used clinical parameters. TheProstatype® Test System measures the expression pattern of three selected and specific prostate cancer embryonic stem cell genes in tumor cell tissue specimens. These expression patterns together with a group of a selected number of known clinical parameters will help the health care professional to predict the disease outcome, the overall survival as well as cancer specific survival of patients.
Show all investments...

BayBG Venture Capital
VC Fund · München, Bayern, Germany · 5 investments in Germany Biotechnology startups

Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Series A, Series B
  • Geography: Germany, Italy, United States

Investor stats

  • Total investments: 115
  • Round size: Series A $428k–$23M; Series B $732k–$10M
  • Lead/follow: 29% lead, 71% follow

Portfolio highlights

  • tado° — Tado° is The Heating App for private homes and small businesses. It adjusts to the residents' behavior in real time and also takes current weather forecasts and building characteristics into account. tado° GmbH is a Munich based Tech Startup bringing Internet of Things into the Cleantech Market. It was founded by Christian Deilmann, JohannesSchwarz, Valentin Sawadski and Leopold von Bismarck in 2011. A team of qualified young professionals has been working on the development of tado° for approximately two years in Munich.
  • IDnow — IDnow provides advanced machine-learning technology for its Identity-as-a-Service platform that can verify identities in real time. The company's solutions guarantee legal security throughout Europe and the highest level of data security. The company provides a legally secure solution without additional hardware in the area of videoidentification of customers and electronic signatures.The company's offer is directed at all business customers who would like to provide customer identification and contract conclusion online, such as banks, telecommunications companies, Fintechs, etc. Its customer portfolio includes renowned firms such as Commerzbank, UBS, Sixt neuwagen, Telefónica, and N26.IDnow was founded on 2014 and is headquartered in Munich, Germany.
  • StoryBox — StoryBox provides a Software as a Service solution for businesses to create, share and structure video content to make it searchable. With the system, companies can create and organize smartphone-based videos for any application scenario. Using the app, videos can be created and shared by every employee using templates. The app suggests picturesettings and scene lengths automatically and offers an automated creation which includes corporate design. The content can be stored in the DSGVO-compliant StoryBox cloud and can be accessed, filtered and analyzed from anywhere. Customers include Iveco, Erste Group, Evonik, Alten, and KTM.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
IBB Ventures
VC Fund · Berlin, Berlin, Germany · 5 investments in Germany Biotechnology startups

Pre-Seed to Series A for Berlin-based founders. Where 30 years of expertise, capital and execution power meet.

Show more...

Investment focus

  • Industry: Software, Health Care, SaaS
  • Stage:Seed, Series A
  • Geography: Germany, United States, United Kingdom

Investor stats

  • Total investments: 206
  • Round size: Seed $1M–$4.6M; Series A $2.2M–$15M
  • Lead/follow: 18% lead, 82% follow
  • Last fund: Likely still investing — raised $33M in 2022

Portfolio highlights

  • Likeminded — Likeminded developed a digital platform for mental health that gives people fast, low-threshold access to psychological support.
  • BOOST Thyroid — Hashimoto's and hypothyroid app. Empowering people with an underactive thyroid to take full control of their own health. Learn more about underactive thyroid on BOOST's website, with articles including the latest research and advice on thyroid health and autoimmunity.
  • dsb Deutsche Sanierungsberatung — dsb Deutsche Sanierungsberatung provides easy and sustainable solutions for climate-friendly homes energy-efficient renovations for homeowners.
Show all investments...

EMBL Ventures
VC Fund · Heidelberg, Baden-Wurttemberg, Germany · 5 investments in Germany Biotechnology startups

EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: Germany, Austria, Ireland

Investor stats

  • Total investments: 11
  • Round size: Series A $3.9M–$15M; Series B $20M–$70M
  • Lead/follow: 27% lead, 73% follow

Portfolio highlights

  • Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
  • Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
  • Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Show all investments...

German Federal Ministry of Research, Technology and Space
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 4 investments in Germany Biotechnology startups

The German Federal Ministry of Research, Technology and Space (BMFTR) funds research programs, promotes in the fields of cutting-edge research, future technologies, innovation and space.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Grant, Seed, Series B
  • Geography: Germany, United States, Denmark

Investor stats

  • Total investments: 58
  • Round size: Seed $340k–$3.3M; Grant $300k–$25M
  • Lead/follow: 55% lead, 45% follow

Portfolio highlights

  • NetBird — Wiretrustee is an open-source VPN platform built on top of WireGuard® making it easy to create secure private networks for your organization or home. It requires zero configuration effort leaving behind the hassle of opening ports, complex firewall rules, VPN gateways, and so forth.
  • CyberTide — CyberTide is an AI-based Data Leak Prevention Solution
  • NVision Imaging Technologies — NVision Imaging Technologies is leveraging advances in quantum physics to enable the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level.
Show all investments...

BlueYard Capital
VC Fund · Berlin, Berlin, Germany · 4 investments in Germany Biotechnology startups

BlueYard backs founders building the interconnected elements that can become the fabric of our future.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Internet
  • Stage:Seed, Series A
  • Geography: United States, Germany, United Kingdom

Investor stats

  • Total investments: 107
  • Round size: Seed $1.2M–$14M; Series A $7M–$47M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: Likely still investing — raised $185M in 2022

Portfolio highlights

  • Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
  • Rapidata — Fast and reliable data labeling that powers your AI. Define your label needs now and get the results in minutes.
  • Insempra — Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance.
Show all investments...

S-Venture Capital Dortmund
VC Fund · Deutsch, Sachsen, Germany · 4 investments in Germany Biotechnology startups

S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.

Show more...

Investment focus

  • Industry: Biotechnology, Guides, Genetics
  • Stage:Series B, Series A
  • Geography: Germany

Investor stats

  • Total investments: 9
  • Round size: Series B $3.6M–$9M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Innolume — Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power.
  • Protagen — Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
  • Scienion — SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields – from early research to manufacturing.
Show all investments...

Seed Fonds Aachen
VC Fund · Aachen, Nordrhein-Westfalen, Germany · 4 investments in Germany Biotechnology startups

Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Seed, Series A
  • Geography: Germany

Investor stats

  • Total investments: 8
  • Round size: Series A $2.2M–$6M
  • Lead/follow: 25% lead, 75% follow

Portfolio highlights

  • miacosa — miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories.
  • Hemovent — ​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.
  • aquila biolabs — aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development.
Show all investments...

CPT Capital
VC Fund · London, England, United Kingdom · 4 investments in Germany Biotechnology startups

Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.

Show more...

Investment focus

  • Industry: Food and Beverage, Biotechnology, Food Processing
  • Stage:Series A, Seed, Series B
  • Geography: United States, Israel, United Kingdom

Investor stats

  • Total investments: 57
  • Round size: Seed $1.3M–$7.5M; Series A $6M–$46M; Series B $15M–$226M
  • Lead/follow: 12% lead, 88% follow

Portfolio highlights

  • Shiru — Discover Shiru. We are an Ingredient Company that Identifies and Creates Functional Ingredients for the Plant-Based Industry.
  • Change Bio — Change Bio converts waste methane into proteins to make them more affordable and carbon-negative.
  • Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
Show all investments...

Grazia Equity
VC Fund · Stuttgart, Baden-Wurttemberg, Germany · 4 investments in Germany Biotechnology startups

Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.

Show more...

Investment focus

  • Industry: Internet, E-Commerce, Biotechnology
  • Stage:Series A, Series B, Seed
  • Geography: Germany, United States, Switzerland

Investor stats

  • Total investments: 83
  • Round size: Seed $1.1M–$8M; Series A $1.1M–$53M; Series B $4M–$59M
  • Lead/follow: 34% lead, 66% follow

Portfolio highlights

  • GYANT — Create more capacity to care. Fabric is the care enablement system powering healthcare to move faster, work smarter, and deliver better care.
  • XO Life — XO Life is to build the largest real-world evidence platform for patient insights for all medications and therapies. Together with one of Europe's leading research institutes for patient-centered research, the PROMIS Institute Germany of the Charité, and various pharmaceutical manufacturers, patient experiences are to be recorded in astandardized and systematic manner across a wide range of diseases. Patients are to be enabled to record their therapy course and outcome independently as well as scientifically validated so that these patient insights from real treatment practice can be used in the life science industry and by medical professions.
  • Mister Spex — Mister Spex is an online store that sells various brands of glasses and contact lenses in Germany. Its product range includes over 5000 different glasses, sunglasses, sports eyewear, and contact lenses from more than 60 brands and designers.The store’s offerings include sports labels such as Adidas, Carrera, Lacoste, and Oakley to designer brandssuch as Burberry, Calvin Klein, Dolce&Gabbana, Gucci, Jil Sander, Prada, Roberto Cavalli, Tom Ford, and Versace.Mister Spex was launched in 2007 and its operations are headquartered in Berlin, Germany. It also operates its own websites in France, Spain, Austria, Switzerland, the Netherlands, and Great Britain.
Show all investments...

better ventures
VC Fund · Hamburg, Hamburg, Germany · 4 investments in Germany Biotechnology startups

At better ventures we invest in early-stage founders who aim to change our world for the better.

Show more...

Investment focus

  • Industry: Software, Food and Beverage, E-Commerce
  • Stage:Pre-Seed, Seed, Series A
  • Geography: Germany, Switzerland

Investor stats

  • Total investments: 41
  • Round size: Seed $1.1M–$5.8M; Pre-Seed $114k–$3.3M
  • Lead/follow: 20% lead, 80% follow

Portfolio highlights

  • repath — Our mission is to make climate risks visible to companies worldwide in order to enable a resilient and future-proof world.
  • SKYSEED — Mit Drohnen und Saatpellets
  • Primogene
Show all investments...

Andera Partners
VC Fund · Paris, Ile-de-France, France · 4 investments in Germany Biotechnology startups

Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Private Equity
  • Geography: France, United States, Germany

Investor stats

  • Total investments: 177
  • Round size: Series B $14M–$85M; Private Equity $110M–$247M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: Likely still investing — raised $466M in 2022

Portfolio highlights

  • MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
  • Amolyt Pharma — AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
  • ImCheck Therapeutics — ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Amino Collective
VC Fund · Berlin, Berlin, Germany · 4 investments in Germany Biotechnology startups

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A, Pre-Seed
  • Geography: United States, United Kingdom, Germany

Investor stats

  • Total investments: 41
  • Round size: Seed $2.4M–$15M; Pre-Seed $125k–$7.8M; Series A $12M–$26M
  • Lead/follow: 2% lead, 98% follow

Portfolio highlights

  • Anima — Anima's online patient triage speeds up the clinical workflow 10x and allows providers to deliver the right care for patients within 24 hours.Millions of patients with serious problems are missed and die every year because there isn’t adequate information flow between medical appointments. Patients submit their problems and requests onAnimainstead of waiting for an appointment, and Anima sends an actionable report to their provider with trends, risks and recommendations.
  • Aware — Aware is a mobile app for evaluating health data and for researching chronic diseases.
  • Lindus — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
Show all investments...

EIC Fund
VC Fund · 4 investments in Germany Biotechnology startups

start-ups, SMEs, technology, co-investment

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Information Technology
  • Stage:Pre-Seed, Seed
  • Geography: Germany, The Netherlands, Austria

Investor stats

  • Total investments: 22
  • Lead/follow: no public data

Portfolio highlights

  • Filuta AI — Operationalized Composite Artificial Intelligence
  • Resistell AG — Resistell is a antibiotic resistance test.
  • iThera Medical — Explore optoacoustic imaging technology for non-invasive in vivo visualization and quantification of disease-related tissue biomarkers.
Show all investments...

LSP BioVentures
VC Fund · Cambridge, Massachusetts, United States · 4 investments in Germany Biotechnology startups

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Germany, United Kingdom

Investor stats

  • Total investments: 26
  • Round size: Series A $5.3M–$176M; Series B $5.3M–$45M; Series C $8M–$100M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: Likely still investing — raised $1.2B in 2022

Portfolio highlights

  • Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
  • iSTAR Medical — iSTAR Medical is a medtech company delivering breakthrough eye care solutions through minimally-invasive implants with bio-integration.
  • HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.
Show all investments...

EQT Ventures
VC Fund · Stockholm, Stockholms Lan, Sweden · 4 investments in Germany Biotechnology startups

EQT Ventures is a European VC fund with just over €2.3 billion in total capital raised. EQT Ventures I launched in May 2016, with commitments totaling €566 million and a simple mission - to be the kind of VC the team would have liked to have had on their own startup journeys. Recognizing that building and growing a company takes more than justcapital, the EQT Ventures team provides founders with support and advice throughout different stages of growth. EQT Ventures doesn't focus on particular markets or industries, but on bold and ambitious founders who have the grit and determination to build global success stories. EQT Ventures II launched in November 2019, with commitments totaling €660 million. EQT Ventures III launched in 2022, with commitments totaling €1.1 billion, making it the biggest European Venture Capital fund committed to early-stage tech startups. The EQT Ventures team is based across six offices in London, Stockholm, Berlin, Paris, Amsterdam, Paris, and San Francisco, taking a locals-with-locals approach and supporting founders on the ground. Motherbrain, EQT Ventures' in-house-developed artificial intelligence (AI) platform, ensures the team has a data-driven approach and has driven more than $100 million in portfolio company investments.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Information Technology
  • Stage:Series A, Seed, Series B
  • Geography: Sweden, Germany, United States

Investor stats

  • Total investments: 231
  • Round size: Seed $3.3M–$14M; Series A $6M–$44M; Series B $15M–$100M
  • Lead/follow: 58% lead, 42% follow
  • Last fund: Likely still investing — raised $1.1B in 2022

Portfolio highlights

  • Unmind — Unmind is a workplace mental health platform. We empower employees to measure, understand, and improve their mental wellbeing.
  • Verkor — Verkor is a battery cell manufacturer whose goal is to increase the production of low-carbon batteries to fulfill the growing demand for electric vehicles. The company focuses on the development of low-carbon batteries with a carbon footprint that is many times smaller than standard batteries. This reduces the logistics footprint, includingemissions, and provides businesses with batteries that are very inexpensive and use carbon-free electricity.
  • Standard Cognition — Standard Cognition is an artificial intelligence platform that allows buyers to grab what they want without having to go to a cashier. It empowers consumers to shop and pay without waiting in line, scanning or stopping to check out. Available to any retailer, the solution helps reduce labor costs, improve the customer experience, and improve profitmargins. It also helps small-size retailers to compete with larger chains and online offerings.Standard Cognition was founded in 2017 and is based in San Francisco, California.
Show all investments...

Counteract
VC Fund · London, England, United Kingdom · 3 investments in Germany Biotechnology startups

Carbon removal innovation through research, development and early stage investment

Show more...

Investment focus

  • Industry: Environmental Engineering, CleanTech, AgTech
  • Stage:Seed, Series A, Pre-Seed
  • Geography: United Kingdom, United States, Germany

Investor stats

  • Total investments: 27
  • Lead/follow: no public data

Portfolio highlights

  • Mote — Mote is creating new gasification technologies to produce cost-competitive carbon-negative hydrogen. We offer hydrogen at scale with our uniquely integrated gasification plant.
  • CREW Carbon — CREW Carbon is on a mission to remove CO2 across Earth's water cycle by first leveraging wastewater systems as a scalable, deployable solution today. We empower the global wastewater sector to lead the fight against climate change.
  • Chloris Geospatial — Chloris Geospatial is able to provide answers today to critical natural capital issues. Chloris Geospatial provides innovative measurements of natural capital that use cutting-edge remote sensing, machine learning, and ecological science.
Show all investments...

Ananda Impact Ventures
VC Fund · Munich, Bayern, Germany · 3 investments in Germany Biotechnology startups

We are the home for entrepreneurs with a big vision who want to create something less ordinary. Something that matters. For all of us.

Show more...

Investment focus

  • Industry: Health Care, Software, Information Technology
  • Stage:Seed, Series A
  • Geography: Germany, United Kingdom, Finland

Investor stats

  • Total investments: 66
  • Lead/follow: no public data

Portfolio highlights

  • Elio — Putting leading scientific data into context, to enable others to respond to climate change’s dynamism and act on solutions with confidence.
  • Ocean Ledger — Precision analytics to design, implement & monitor coastal mitigation and adaptation.
  • NatureMetrics — NatureMetrics is the World-Leading provider of Biodiversity monitoring data, using eDNA surveys, metabarcoding & more. Book your demo today!
Show all investments...

EQT Life Sciences
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 3 investments in Germany Biotechnology startups

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, The Netherlands, Switzerland

Investor stats

  • Total investments: 161
  • Lead/follow: no public data

Portfolio highlights

  • Cyted — Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use AI and novel biomarkers to improve patient outcomes.
  • Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
  • Avidicure — Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer
Show all investments...

TechVision Fund
VC Fund · Aachen, Nordrhein-Westfalen, Germany · 3 investments in Germany Biotechnology startups

VF-Funds for innovative and scalable start-ups from the Rhineland Area, Germany

Show more...

Investment focus

  • Industry: Software, Health Care, Manufacturing
  • Stage:Seed, Series A, Pre-Seed
  • Geography: Germany, Spain

Investor stats

  • Total investments: 27
  • Lead/follow: no public data

Portfolio highlights

  • IonKraft — IonKraft's barrier coating technology for plastic packaging, offers excellent product protection while being 100% recyclable.
  • Eeden — Eeden engages in the manufacture and supply of textiles.
  • Planted Green — Planted Green plants mixed forests to compensate for CO2 emissions.
Show all investments...

DvH Ventures
VC Fund · Köln, Nordrhein-Westfalen, Germany · 3 investments in Germany Biotechnology startups

Investing early in Europe's most passionate founders.

Show more...

Investment focus

  • Industry: Health Care, Financial Services, FinTech
  • Stage:Seed, Series A
  • Geography: Germany, Austria, United Kingdom

Investor stats

  • Total investments: 70
  • Lead/follow: no public data

Portfolio highlights

  • LiveEO — LiveEO is the leading solution provider for AI-powered satellite-based monitoring of large infrastructure networks. Trusted worldwide.
  • Buynomics — buynomics is the leading solution to optimize your product portfolio. Our clients use buynomics to optimize pricing, promotions, & portfolio architecture.
  • HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
Show all investments...

Gruenderfonds Ruhr
VC Fund · Essen, Nordrhein-Westfalen, Germany · 3 investments in Germany Biotechnology startups

Gruenderfonds Ruhr is an investment firm.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Information Technology
  • Stage:Series A, Series B, Seed
  • Geography: Germany

Investor stats

  • Total investments: 10
  • Round size: Series A $4.9M–$95M; Series B $16M–$35M
  • Lead/follow: 10% lead, 90% follow

Portfolio highlights

  • Lidrotec — Lidrotec aim to expand the application potential of processing with ultra-short pulse lasers.
  • iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
  • Otter Energy Trading — Otter Energy Trading is creating a marketplace where producers and customers may exchange electricity automatically.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Kurma Partners
VC Fund · Paris, Ile-de-France, France · 3 investments in Germany Biotechnology startups

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Seed, Series B
  • Geography: France, Switzerland, Spain

Investor stats

  • Total investments: 128
  • Round size: Seed $2.3M–$13M; Series A $3.8M–$74M; Series B $8.8M–$80M
  • Lead/follow: 50% lead, 50% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • Medlumics — Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.
  • Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
  • Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Show all investments...

Agronomics
VC Fund · Douglas, South Lanarkshire, United Kingdom · 3 investments in Germany Biotechnology startups

Venture capital investment can raise funds for your small business. Venture Capital Firms in the UK like Agronomics is a biotech venture capital firm which invest into the clean meat sector.

Show more...

Investment focus

  • Industry: Biotechnology, Food and Beverage, Food Processing
  • Stage:Series A, Seed, Series B
  • Geography: United States, Finland, Germany

Investor stats

  • Total investments: 44
  • Round size: Seed $894k–$11M; Series A $6M–$47M; Series B $2.4M–$55M
  • Lead/follow: 48% lead, 52% follow

Portfolio highlights

  • BlueNalu — BlueNalu's mission is to be the global leader in cellular aquaculture, providing consumers with great tasting, healthy, safe, and trusted seafood products that support the sustainability and diversity of our oceans.
  • Onego Bio — Onego Bio is a cell ag company, specialized in animal-free egg white protein. We produce bioalbumen with an innovative precision fermentation process.
  • Liberation Bioindustries — Liberation Labs believe that by innovating technology, It can free the world from the costs of industrialized agriculture and unlock a new era of accessible, healthy foods. The mission is to make precision fermentation by commercializing purpose-built manufacturing facilities for industrial biotech.
Show all investments...

Elevat3 Capital
VC Fund · 3 investments in Germany Biotechnology startups

Elevat3 Capital is the venture capital arm of serial entrepreneur and investor Christian Angermayer and his family office Apeiron Investment Group. With a focus on German-speaking countries, we partner with companies that meet our three-level criteria, then elevate them by providing more than just capital. We use our exceptional network, spanningindustry, politics, arts, science and technology, to give our portfolio companies access to high-profile leads and advisors, enabling them to grow rapidly and achieve amazing results.

Show more...

Investment focus

  • Industry: FinTech, Apps, Social
  • Stage:Series A, Series B, Post-IPO Equity
  • Geography: Germany, United Kingdom

Investor stats

  • Total investments: 6
  • Round size: Series A $45M–$157M
  • Lead/follow: 83% lead, 17% follow

Portfolio highlights

  • Formo — Formo is shaping the future of dairy with precision fermentation, creating animal-free recombinant milk proteins with exceptional functionality.
  • Naga — NAGA is disrupting the worlds of trading and investment by making them more open and inclusive. It is the single solution that's got it all: Trade, Earn, Invest, Acquire, Connect, Pay; all in one seamless and unified ecosystem that is radically social! Traders and investors from all around the world can use the NAGA technology every day inmany powerful ways: invest in the financial markets (physical stocks, CFDs in stocks, indices, currencies, energies, metals, commodities and cryptocurrencies), make payments in fiat and cryptocurrency, learn about wealth as well as communicate and connect with like-minded people anywhere and anytime. NAGA expands the one-of-a-kind experience with many other unique and innovative services such as the NAGA Mastercard, the AI-driven Portfolio baskets, the world’s first messenger where traders can exchange ideas and opinions in its public channels, Auto-Copying other traders and copying trading signals thanks to the revolutionary NAGA Signals feature.NAGA is really greater than the sum of its parts and powerful when its full spectrum of products and features are used together.
  • Legendairy Foods — Formo is shaping the future of dairy with precision fermentation, creating animal-free recombinant milk proteins with exceptional functionality.
Show all investments...

Taavet Hinrikus
Angel · London, England, United Kingdom · 3 investments in Germany Biotechnology startups

Taavet Hinrikus is based out of London, England and is the Partner of Plural Platform and Board Member of CoMind. Taavet previously worked at Wise as a Chairman and Co-founder. Taavet Hinrikus attended INSEAD.

Show more...

Investment focus

  • Industry: FinTech, Software, Financial Services
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Estonia

Investor stats

  • Total investments: 125
  • Round size: Seed $1M–$7.9M; Series A $7M–$47M; Series B $23M–$52M
  • Lead/follow: 15% lead, 85% follow

Portfolio highlights

  • Juro — Juro is an all-in-one contract automation platform that helps legal and business users to agree & manage contracts in one unified workspace.
  • Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
  • Skeleton Technologies — Skeleton Technologies is the global leader in ultracapacitor & supercapacitor energy storage and helps companies in automotive, transportation, grid, and industry to save energy.
Show all investments...

TVM Capital
VC Fund · Munich, Bayern, Germany · 3 investments in Germany Biotechnology startups

TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series B, Series C
  • Geography: United States, Germany, United Kingdom

Investor stats

  • Total investments: 102
  • Round size: Series B $7.5M–$50M; Series C $10M–$55M
  • Lead/follow: 19% lead, 81% follow
  • Last fund: May invest from a new fund soon — raised $290M in 2005

Portfolio highlights

  • Definiens — Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
  • Lamab Biologics — Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.
  • Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Show all investments...

Think.Health
VC Fund · Fürstenfeldbruck, Bayern, Germany · 3 investments in Germany Biotechnology startups

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Seed, Series A, Series B
  • Geography: Germany, United States, France

Investor stats

  • Total investments: 34
  • Round size: Seed $1.1M–$8.7M; Series A $3.6M–$28M
  • Lead/follow: 35% lead, 65% follow

Portfolio highlights

  • Robeaute — Redesigning the future of neurosurgery by creating the new standard device that will provide surgeons with seamless access to delicate areas of the brain parenchyma and with real-time data.
  • Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
  • Sphingotec GmbH — Improving patient outcomes with innovative diagnostics for critical care: Actionable insights in real-time
Show all investments...

Andrew Keys
Angel · 3 investments in Germany Biotechnology startups

Andrew Keys is the Co-Founder and Managing Partner of Andrew Keys. He previously worked for ConsenSys as a Head of Global Business Development. Andrew Keys attended Loyola University Maryland.

Show more...

Investment focus

  • Industry: Software, Finance, Blockchain
  • Stage:Seed, Pre-Seed, Series A
  • Geography: United States, India, Norway

Investor stats

  • Total investments: 14
  • Round size: Seed $1M–$34M; Pre-Seed $1.4M–$2.5M; Series A $14M–$15M
  • Lead/follow: 7% lead, 93% follow

Portfolio highlights

  • Stackr Labs — Micro-rollups to scale web3 applications
  • Zivoe Finance — Join Zivoe in disrupting predatory high-interest lending.
  • Ithaca Finance — Ithaca Finance a cross-chain derivatives trading and settlements protocol, is composed of an on-chain settlement layer with an innovative off-chain matching engine.
Show all investments...

OCCIDENT
VC Fund · Zug, Zug, Switzerland · 3 investments in Germany Biotechnology startups

Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Series A, Series B, Series C
  • Geography: Germany, Switzerland, Slovenia

Investor stats

  • Total investments: 26
  • Round size: Series A $2.1M–$12M; Series B $6.2M–$140M; Series C $7.8M–$24M
  • Lead/follow: 31% lead, 69% follow

Portfolio highlights

  • ReCatalyst — REvolutionizing the way we make CATALYSTs for hydrogen technologies
  • Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.
  • Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Show all investments...

Good Seed Ventures
VC Fund · Rheine, Nordrhein-Westfalen, Germany · 3 investments in Germany Biotechnology startups

Good Seed Ventures is a Venture Capital firm that exclusively invests in sustainable food tech.

Show more...

Investment focus

  • Industry: Food and Beverage, Food Processing, Biotechnology
  • Stage:Seed, Series A, Pre-Seed
  • Geography: Germany, Israel, United States

Investor stats

  • Total investments: 31
  • Round size: Seed $25k–$7M; Series A $6.7M–$21M
  • Lead/follow: 16% lead, 84% follow

Portfolio highlights

  • Lovely Day Foods — We harness the power of plants and cutting-edge technology to crack the egg.
  • Libre Foods — MEAT, BUT MAKE IT MUSHROOMS. GET READY TO TASTE THE POWER OF FUNGI
  • Nosh Biofoods — We create nutritional and highly functional proteins from non-GMO fungi. Our proprietary ferementation process is minimal, scalable, and sustainable.
Show all investments...

M Ventures
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 3 investments in Germany Biotechnology startups

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Switzerland

Investor stats

  • Total investments: 163
  • Round size: Seed $2.4M–$21M; Series A $5.2M–$45M; Series B $15M–$100M
  • Lead/follow: 39% lead, 61% follow

Portfolio highlights

  • CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
  • UNISERS — Developing solutions for Universal Contamination Analysis. Working with cutting edge technologies to revolutionize contamination control.
  • Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
Show all investments...

Biotechnology Investor funding in Germany at a glance

Stats across 636 deals from 701 investors.

701
investors
in Germany Biotechnology startups
636
deals
in Germany Biotechnology startups
$7.7M
median round
in Germany Biotechnology startups
37%
lead investors
lead at least one round
20%
Seed
most common funding stage
89/11
VC / Angel
share of investor count

Access all 701 investors in Germany Biotechnology startups.

Open List

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotechnology Investors in Germany investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 701 investors investing in Germany Biotechnology startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists